Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Zhang, Y., Karagiannis, D., Liu, H., Lin, M., Fang, Y., Jiang, M., Chen, X., Suresh, S., Huang, H., She, J., Shi, F., Liu, J., Luo, D., Angel, J. C., Lin, G., Yang, P., El-Rifai, W., Zaika, A., Oro, A. E., … Que, J. (2024). Epigenetic regulation of p63 blocks squamous-to-neuroendocrine transdifferentiation in esophageal development and malignancy. Science Advances, 10(41). https://doi.org/10.1126/sciadv.adq0479

Neugut, A. I., & Bates, S. E. (2024). Highlights of ASCO 2024. The Oncologist, 29(11), 913–917. https://doi.org/10.1093/oncolo/oyae250

Jamison, J. K., Zhou, M., Gelmann, E. P., Luk, L., Bates, S. E., Califano, A., & Fojo, T. (2024). Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. The Oncologist. https://doi.org/10.1093/oncolo/oyae118

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Oxnard, G. R., Chen, R., Pharr, J. C., Koeller, D. R., Bertram, A. A., Dahlberg, S. E., Rainville, I., Shane-Carson, K., Taylor, K. A., Sable-Hunt, A., Sholl, L. M., Teerlink, C. C., Thomas, A., Cannon-Albright, L. A., Fay, A. P., Ashton-Prolla, P., Yang, H., Salvatore, M. M., Addario, B. J., … Garber, J. E. (2023). Germline EGFR Mutations and Familial Lung Cancer. Journal of Clinical Oncology, 41(34), 5274–5284. https://doi.org/10.1200/jco.23.01372

Safari, M., Scotto, L., Litman, T., Petrukhin, L. A., Zhu, H., Shen, M., Robey, R. W., Hall, M. D., Fojo, T., & Bates, S. E. (2023). Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms. Cancers, 15(20), 4960. https://doi.org/10.3390/cancers15204960

Farha, N., Wei, W., Mundi, P., Krishnamurthi, S., Steele, S., Kamath, S., Gorgun, E., Liska, D., Estfan, B., Khorana, A., & Laderian, B. (2023). P-273 Genomic signatures associated with aggressive histology and decreased overall survival in neuroendocrine malignancies. Annals of Oncology, 34, S112. https://doi.org/10.1016/j.annonc.2023.04.329

Herzberg, B. O., & Manji, G. A. (2023). KRAS: Druggable at Last. The Oncologist, 28(4), 283–286. https://doi.org/10.1093/oncolo/oyad014

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008

Olazagasti, C., Ehrlich, M., & Seetharamu, N. (2022). One size does not fit all: Evaluating disparities in lung cancer screening eligibility amongst the Hispanic population. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.995408

Yap, T. A., Moore, K. N., Patel, M., Henick, B. S., Do, D., Iheanacho, A., Zhang, H., Roche, M., Newberry, K., Hsieh, A., & Juric, D. (2022). 491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors. Annals of Oncology, 33, S765. https://doi.org/10.1016/j.annonc.2022.07.619

Ricciuti, B., Wang, X., Alessi, J. V., Rizvi, H., Mahadevan, N. R., Li, Y. Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N. I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V. R., Leonardi, G. C., Plodkowski, A. J., Gupta, H., Cherniack, A. D., … Awad, M. M. (2022). Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 8(8), 1160. https://doi.org/10.1001/jamaoncol.2022.1981

Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., Hellmann, M. D., Hirsch, F. R., Johnson, M. L., Malik, S., Morgensztern, D., Neal, J. W., Patel, J. D., Rimm, D. L., Sagorsky, S., … Herbst, R. S. (2022). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for ImmunoTherapy of Cancer, 10(5), e003956. https://doi.org/10.1136/jitc-2021-003956

Biswas, A. K., Han, S., Tai, Y., Ma, W., Coker, C., Quinn, S. A., Shakri, A. R., Zhong, T. J., Scholze, H., Lagos, G. G., Mela, A., Manova-Todorova, K., de Stanchina, E., Ferrando, A. A., Mendelsohn, C., Canoll, P., Yu, H. A., Paik, P. K., Saqi, A., … Acharyya, S. (2022). Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse inEGFR-Mutant Lung Cancer. Cancer Discovery, 12(4), 1002–1021. https://doi.org/10.1158/2159-8290.cd-21-0910

Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., Jordan, J. T., Lassman, A. B., Maues, J., Mohile, N., Redjal, N., Stevens, G., Sulman, E., van den Bent, M., Wallace, H. J., … Schiff, D. (2021). Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Neuro-Oncology, 24(3), 331–357. https://doi.org/10.1093/neuonc/noab262